Market Overview:
The global anticoagulant treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of thrombotic disorders, increasing geriatric population, and technological advancements in the field of anticoagulants. However, the high cost associated with these drugs is likely to restrain the growth of this market during the forecast period. The global anticoagulant treatment market is segmented on the basis of type into NOACs (direct oral anticoagulants), heparin, warfarin, and others. The NOACs segment is expected to grow at a CAGR of 6% from 2018 to 2030 owing to its advantages over other types of anticoagulants such as ease-of-use and fewer side effects. On the basis of application, this market is segmented into hospitals, drug stores, and others segments.
Product Definition:
An anticoagulant (or blood thinner) is a substance that prevents or slows the coagulation of blood, prolonging the clotting time. Anticoagulants are used to treat and prevent thrombosis (formation of a thrombus), pulmonary embolism, and deep vein thrombosis.
NOACs:
Non-Vascular Endothelial Abnormalities (NOACs) are a group of vascular diseases that includes deep vein thrombosis and pulmonary embolism. According to the American Society for Clinical Oncology (ASCO), approximately 6 million people in the U.S alone suffer from deep vein thrombosis or DVT every year, which leads to around 600,000 deaths annually.
Heparin:
Heparin is a type of blood thinner. It works by reducing the ability of the blood to clot. Heparin products are used in anticoagulant treatment, which is also known as coagulation therapy or internal bleeding. Coagulation includes factors such as platelets aggregation and fibrin formation leading to bleeding disorders or thrombocytopenia (low platelet count).
Application Insights:
The other application segment includes home healthcare and self-administration. The use of anticoagulants in patients undergoing surgery or trauma is increasing owing to the rising incidence of such diseases. According to the American Heart Association, more than 3.5 million people suffered from TTI in 2015, which was a significant increase from 1999 when about 2 million Americans were affected by this condition every year.
Drug stores are expected to be the fastest-growing segment due to factors such as availability of low cost and high quality generic drugs that are manufactured in large quantities at a lower price compared with branded products sold through hospital pharmacies or clinics. This trend is likely to continue over the forecast period as treatment costs less hence generating huge revenue for manufacturers operating within this market space Overdose accounted for nearly 20% of deaths caused by VTE among hospitalized patients according to data published by CDC in 2012 (epidemiology).
Regional Analysis:
North America dominated the global anticoagulant treatment market in 2017. This is due to favorable reimbursement policies, presence of key manufacturers and well-established healthcare infrastructure. In addition, increasing incidence of blood clots is one of the major factors responsible for its large share. According to a study published in NCBI, around 6 million people suffer from deep vein thrombosis (DVT) and 3 million cases suffer from pulmonary embolism (PE) annually in U.S.
Asia Pacific region is expected to witness lucrative growth over the forecast period owing to rising geriatric population prone to various chronic diseases such as cardiovascular disorders, cancer.
Growth Factors:
- Increasing incidence of thrombotic disorders: The global anticoagulant treatment market is expected to grow at a CAGR of 5.5% during the forecast period, owing to the increasing incidence of thrombotic disorders such as deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (MI).
- Growing geriatric population: The geriatric population is more susceptible to developing blood clots and other related health conditions, which is expected to drive the demand for anticoagulant treatments in the coming years.
- Technological advancements: The development of novel oral anticoagulants (NOACs) has revolutionized the treatment landscape for patients with clotting disorders, thereby boosting market growth. These drugs are easier to administer and have a lower risk of bleeding than traditional warfarin therapy.
- Rising awareness about blood clot prevention: There has been an increase in awareness among people about blood clot prevention measures such as regular exercise, healthy diet, and use of compression stockings/devices etc., which is likely to propel market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Anticoagulant Treatment Market Research Report
By Type
NOACs, Heparin, Warfarin, Others
By Application
Hospital, Drugs Stores, Other
By Companies
Bristol-Myers Squibb, Bayer, Pfizer, Johnson & Johnson, Sanofi, Boehringer Ingelheim, Daiichi Sankyo
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
161
Number of Tables & Figures
113
Customization Available
Yes, the report can be customized as per your need.
Global Anticoagulant Treatment Market Report Segments:
The global Anticoagulant Treatment market is segmented on the basis of:
Types
NOACs, Heparin, Warfarin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Stores, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- Bayer
- Pfizer
- Johnson & Johnson
- Sanofi
- Boehringer Ingelheim
- Daiichi Sankyo
Highlights of The Anticoagulant Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- NOACs
- Heparin
- Warfarin
- Others
- By Application:
- Hospital
- Drugs Stores
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anticoagulant Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anticoagulant treatment is a medical procedure that helps to prevent blood from clotting. This can be done by using medications, devices, or surgery.
Some of the major companies in the anticoagulant treatment market are Bristol-Myers Squibb, Bayer, Pfizer, Johnson & Johnson, Sanofi, Boehringer Ingelheim, Daiichi Sankyo.
The anticoagulant treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anticoagulant Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anticoagulant Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anticoagulant Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anticoagulant Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anticoagulant Treatment Market Size & Forecast, 2018-2028
4.5.1 Anticoagulant Treatment Market Size and Y-o-Y Growth
4.5.2 Anticoagulant Treatment Market Absolute $ Opportunity
Chapter 5 Global Anticoagulant Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Anticoagulant Treatment Market Size Forecast by Type
5.2.1 NOACs
5.2.2 Heparin
5.2.3 Warfarin
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Anticoagulant Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Anticoagulant Treatment Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drugs Stores
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anticoagulant Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anticoagulant Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Anticoagulant Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Anticoagulant Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Anticoagulant Treatment Market Size Forecast by Type
9.6.1 NOACs
9.6.2 Heparin
9.6.3 Warfarin
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Anticoagulant Treatment Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drugs Stores
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Anticoagulant Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Anticoagulant Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Anticoagulant Treatment Market Size Forecast by Type
10.6.1 NOACs
10.6.2 Heparin
10.6.3 Warfarin
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Anticoagulant Treatment Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drugs Stores
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Anticoagulant Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Anticoagulant Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Anticoagulant Treatment Market Size Forecast by Type
11.6.1 NOACs
11.6.2 Heparin
11.6.3 Warfarin
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Anticoagulant Treatment Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drugs Stores
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Anticoagulant Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Anticoagulant Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Anticoagulant Treatment Market Size Forecast by Type
12.6.1 NOACs
12.6.2 Heparin
12.6.3 Warfarin
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Anticoagulant Treatment Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drugs Stores
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Anticoagulant Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Anticoagulant Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Anticoagulant Treatment Market Size Forecast by Type
13.6.1 NOACs
13.6.2 Heparin
13.6.3 Warfarin
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Anticoagulant Treatment Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drugs Stores
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anticoagulant Treatment Market: Competitive Dashboard
14.2 Global Anticoagulant Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb
14.3.2 Bayer
14.3.3 Pfizer
14.3.4 Johnson & Johnson
14.3.5 Sanofi
14.3.6 Boehringer Ingelheim
14.3.7 Daiichi Sankyo
